Tafalgie Therapeutics

Executive Summary

Tafalgie Therapeutics is a clinical-stage biotechnology company based in Marseille, France, spun out from CNRS in 2020. The company is pioneering a novel class of non-opioid analgesics aimed at providing a safe and effective alternative to existing painkillers, including opioids. Its lead molecule is currently in Phase 1 clinical development, targeting pain pathways distinct from traditional opioids to avoid addiction and severe side effects. With a focus on next-generation pain management, Tafalgie addresses a critical unmet need in the global pain therapeutics market, which is plagued by the opioid crisis and limited efficacy of current treatments.

Upcoming Catalysts (preview)

• Q1 2025Phase 1 Clinical Trial Results40% success
• TBDPartnership or Licensing Deal25% success
• TBDSeries A or Grant Funding50% success